SCH 6
Alternative Names: SCH-446211; SCH-6Latest Information Update: 23 Sep 2010
At a glance
- Originator Dendreon Corporation; Schering-Plough
- Developer Schering-Plough
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 30 Aug 2007 No development reported - Phase-I for Hepatitis C in USA (PO)
- 20 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the pharmacokinetics and Viral infections pharmacodynamics sections
- 05 Jan 2004 The activities of Dendreon San Diego LLC are being relocated to Dendreon's Seattle headquarters